Dabigatran or warfarin for extended maintenance therapy of venous thromboembolism

被引：0
|
作者：
Schulman, S. [1 ]
Eriksson, H. [2 ]
Goldhaber, S. Z. [3 ]
Kakkar, A. K. L. [4 ,5 ]
Kearon, C. [6 ]
Kvamme, A. M. [7 ]
Mismetti, P. [8 ]
Schellong, S. [9 ]
Schnee, J. [10 ]
机构：
[1] HHS Gen Hosp, Thrombosis Serv, Hamilton, ON, Canada
[2] Sahlgrenska Univ Hosp Oestra, Dept Med, Gothenburg, Sweden
[3] Harvard Univ, Sch Med, Brigham & Womens Hosp, Boston, MA USA
[4] Thrombosis Res Inst, London SW3 6LR, England
[5] Queen Mary Univ London, London, England
[6] McMaster Univ, Dept Med, Hamilton, ON, Canada
[7] Boehringer Ingelheim GmbH & Co KG, Dept Med, Oslo, Norway
[8] Bellevue Hosp, Dept Vasc Pathol, St Etienne, France
[9] Municipal Hosp Friedrichstadt, Med Div 2, Dresden, Germany
[10] Boehringer Ingelheim Pharmaceut Inc, Ridgefield, CT 06877 USA
来源：
JOURNAL OF THROMBOSIS AND HAEMOSTASIS | 2011年 / 9卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
O-TH-033
引用
收藏
页码：731 / 732
页数：2
相关论文
共 50 条
  • [31] DABIGATRAN IN DEEP VENOUS THROMBOSIS REFRACTORY TO WARFARIN
    Sharifi, Mohsen
    Bay, Curt
    Schuster, Todd
    Mehdipour, Navid
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2012, 59 (13) : E1700 - E1700
  • [32] Insights from the dabigatran versus warfarin trial in patients with venous thromboembolism (the RE-COVER trial)
    Prandoni, Paolo
    Taher, Ali
    EXPERT OPINION ON PHARMACOTHERAPY, 2010, 11 (06) : 1035 - 1037
  • [33] Extended therapy for unprovoked venous thromboembolism: when is it indicated?
    Tritschler, Tobias
    Wells, Philip S.
    BLOOD ADVANCES, 2019, 3 (03) : 499 - 499
  • [34] A Randomized Trial of Dabigatran Versus Warfarin in the Treatment of Acute Venous Thromboembolism (RE-COVER II)
    Schulman, Sam
    Kakkar, Ajay K.
    Schellong, Sebastian M.
    Goldhaber, Samuel Z.
    Henry, Eriksson
    Mismetti, Patrick
    Christiansen, Anita Vedel
    Schnee, Janet
    Kearon, Clive
    BLOOD, 2011, 118 (21) : 95 - 96
  • [35] Dabigatran Versus Warfarin in the Treatment of Acute Venous Thromboembolism. Results of the RE-COVER study
    Lyakishev, A. A.
    KARDIOLOGIYA, 2010, 50 (03) : 80 - 81
  • [36] Low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism
    Cosmi, B
    Palareti, G
    NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (04): : 399 - 399
  • [37] Long-term dabigatran therapy reduces the risk of recurrent venous thromboembolism
    Megan Cully
    Nature Reviews Cardiology, 2013, 10 (5) : 240 - 240
  • [38] Dabigatran etexilate for venous thromboembolism: a safety evaluation
    Brown, Richard
    Lip, Gregory Y. H.
    Gallego, Pilar
    EXPERT OPINION ON DRUG SAFETY, 2014, 13 (05) : 639 - 647
  • [39] Dabigatran For The Treatment And Secondary Prevention Of Venous Thromboembolism
    Stevanovic, J.
    Kappelhoff, B.
    Voorhaar, M.
    Postma, M. J.
    VALUE IN HEALTH, 2015, 18 (07) : A393 - A393
  • [40] Dabigatran Etexilate: A Review in Pediatric Venous Thromboembolism
    Julia Paik
    Pediatric Drugs, 2022, 24 : 423 - 431
12345